Amunix Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Amunix Pharmaceuticals's estimated annual revenue is currently $13.8M per year.
- Amunix Pharmaceuticals's estimated revenue per employee is $155,000
- Amunix Pharmaceuticals's total funding is $190M.
Employee Data
- Amunix Pharmaceuticals has 89 Employees.
- Amunix Pharmaceuticals grew their employee count by -26% last year.
Amunix Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Amunix Pharmaceuticals?
Amunix is leveraging our expertise in precision protein engineering to enable the promise of T cell engagers in solid tumors. Our goal is to save cancer patientsￃﾢ￢ﾂﾬ￢ﾄﾢ lives through the development and commercialization of breakthrough therapies that harness the immune system. We have invented XTEN, a validated therapeutic half-life extension technology. Our current focus is Pro-XTEN, a next-generation protease activated pro-drug platform, which enables selective activation of potent cancer therapies in the tumor microenvironment. This overcomes a common challenge facing potent immune system activators: on-target, off-tumor toxicity. Amunixￃﾢ￢ﾂﾬ￢ﾄﾢs two lead programs employ the Pro-XTEN technology to enhance the safety profile of T cell engagers. XPATs (XTENylated Protease-Activated T Cell Engagers) have the potential to make off-the-shelf therapies redirecting T cells to solid tumors a reality. Amunixￃﾢ￢ﾂﾬ￢ﾄﾢs robust technology has been validated through multiple collaborations with leading biopharmaceutical companies including Celgene, Genentech, Janssen, Roche, and Bioverativ (now Sanofi). In addition, XTENylated drugs have been dosed in greater than 200 patients with minimal immunogenicity against XTEN. Amunix is currently located in Mountain View, CA but is moving to South San Francisco in 2020.
keywords:N/A
$190M
Total Funding
89
Number of Employees
$13.8M
Revenue (est)
-26%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Amunix Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Medical Officer | Reveal Email/Phone |
2 | Director: Analytical Development and Mass Spectrometry | Reveal Email/Phone |
3 | Director, Bioanalytical Sciences | Reveal Email/Phone |
4 | Director Pharmacology and Preclinical Development | Reveal Email/Phone |
5 | Associate Director, Translational Biomarkers | Reveal Email/Phone |
6 | Senior Clinical Trial Manager | Reveal Email/Phone |
7 | Director, Process Development | Reveal Email/Phone |
8 | Account Manager | Reveal Email/Phone |
9 | Executive Director, Clinical Pharmacology | Project Team Leader | Reveal Email/Phone |
10 | Head Clinical Data Management | Reveal Email/Phone |
Amunix Pharmaceuticals News
Amunix Pharmaceuticals, Inc., a South San Francisco, CA-based biopharmaceutical company focused on developing masked, protease-activated immune-oncology therapeutics to bring the promise of these potent therapies to patients with solid tumor cancers, raised $117m in Series B financing. The roun ...
Biopharma startup Amunix has raised $117 million in a Series B led by Viking Global, with support from Bain Capital Life Sciences, BlackRock, Avidity Capital, Omega Funds, ArrowMark Partners and others. The South San Francisco-based company is working to treat solid tumor cancers; its drug pipel ...
Exactly one year after Amunix Pharmaceuticals raised $73 million, the tech-licensing company turned cancer biotech is drawing another $117 million from the venture capital well. The funds will fuel the development of T-cell engager and cytokine treatments for solid tumors, including the advancem ...
Other Companies in Mountain View
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $9.1M | 89 | 2% | N/A |
#2 | $9.1M | 89 | 71% | N/A |
#3 | $24M | 89 | -14% | $9.3M |
#4 | $12.6M | 90 | 2% | $102.5M |
#5 | $22.1M | 90 | -4% | N/A |
Amunix Pharmaceuticals Executives
| Name | Title |
|---|---|
| Angie You | CEO |
| Maninder Hora | Chief Technical Operations Officer |
| Mika Derynck | Chief Medical Officer |
| Darcy Mootz | Chief Business Officer |
| Zeeshan Merchant | Chief Financial Officer |
| Zeeshan Merchant | CFO |
| Volker Schellenberger | President & CTO |
| Nicky Barber | Senior Vice President Finance & Accounting |
| Kim Baxter | VP of Quality |
| Bee-Cheng Sim | Director to Vice President, Discovery Biology & Preclinical Development |
| Robert Jones | Vice President of Contracts |
| Geetha Shankar | VP, Clinical Science and Clinical Operations |
| Gary Taniguchi | Vice President, BioAnalytical Sciences |
| Ursula McCurry | Vice President Clinical Operation |
| Katherine Zafereo | Vice President Investor Relations & Corporate Communications |